THUR 058 Eslicarbazepine acetate as monotherapy in clinical practice

Simple item page
AudienciaPúblico en generales_ES
CoberturaMéxicoes_ES
Fecha de ingreso2026-09-15T00:32:11Z
Fecha de publicación2018-01-01
ResumenPurposeTo assess eslicarbazepine acetate (ESL) as monotherapy in everyday clinical practice.MethodEuro-Esli was a pooled analysis of 14 European studies. In a subanalysis, data were compared for patients treated initially with ESL monotherapy versus adjunctive therapy, and for patients treated at last visit with ESL monotherapy versus adjunctive therapy.Assessments included responder rate (≥50% seizure frequency reduction), seizure freedom rate (seizure freedom at least since prior visit) and incidence of adverse events (AEs).ResultsESL was used as monotherapy in 88/2045 and 229/1340 patients initially and at last visit, respectively. At 12 months, responder and seizure freedom rates were significantly higher in patients treated initially with ESL monotherapy versus adjunctive therapy (responder: 94.1% versus 74.8%; seizure freedom: 88.2% versus 39.0%), and in patients treated at last visit with ESL monotherapy versus adjunctive therapy (responder: 93.2% versus 70.4%; seizure freedom: 77.4% versus 25.9%). Overall incidence of AEs was similar in patients treated initially with ESL monotherapy and adjunctive therapy (29.4% versus 34.4%), and in patients treated at last visit with ESL monotherapy and adjunctive therapy (27.1% versus 30.8%).ConclusionESL was significantly more effective when used as monotherapy compared with adjunctive therapy; safety/tolerability was generally comparable.Supported by Eisaies_ES
Doihttps://doi.org/10.1136/jnnp-2018-abn.25es_ES
URIhttps://riuat.uat.edu.mx/handle/123456789/3682
Idiomaenes_ES
EditorialBMJes_ES
RelaciónJournal of Neurology, Neurosurgery & Psychiatryes_ES
URL relacionadohttps://doi.org/10.1136/jnnp-2018-abn.25es_ES
DerechosAcceso restringido / Suscripción (Metadatos de producción científica)es_ES
Licenciahttp://purl.org/coar/access_right/c_16eces_ES
FuenteJournal of Neurology, Neurosurgery & Psychiatry
TítuloTHUR 058 Eslicarbazepine acetate as monotherapy in clinical practicees_ES
TipoArtículoes_ES
ArbitradoHa sido Arbitradoes_ES
AutorRob, McMurray
AutorNorman, Delanty
AutorVicente, Villanueva
AutorRob, McMurrayes_ES
AutorNorman, Delantyes_ES
AutorVicente, Villanuevaes_ES
InstituciónUniversidad Autónoma de Tamaulipas
InstituciónUniversidad Autónoma de Tamaulipases_ES
Número10es_ES
Rango de páginasA7.1-A7es_ES
URL relacionadahttps://doi.org/10.1136/jnnp-2018-abn.25
Tipo de artículoIndexado
Tipo de artículoIndexadoes_ES
Volumen89es_ES

Files

Collections

Documentación Cientifica